Retatrutide 5 Mg
Retatrutide (LY3437943) is an investigational peptide originally developed by Eli Lilly. It is designed to act on three key receptors in the body: GLP-1, GIP, and glucagon. Because of this, researchers are studying it for weight management, type 2 diabetes, and other metabolic conditions such as NAFLD and MASH. The 5 mg presentation refers to the total peptide content in the vial. Like other versions, retatrutide is a long-acting compound with an approximate half-life of six days. In research settings, it is commonly administered through subcutaneous injection, which supports once-weekly dosing protocols. This peptide is provided as a lyophilized (freeze-dried) powder. It typically shows high purity levels of around 98–99% when tested by HPLC. Before use in research, it must be properly reconstituted under controlled conditions. As of 2026, retatrutide is still in phase 3 clinical trials under the TRIUMPH program. It has not been approved by the FDA, EMA, or MHRA. It is not available for medical use, compounding, or personal consumption. Retatrutide is strictly intended for laboratory research, including in vitro studies, animal testing, and approved clinical trials.
How Retatrutide Works in Research
Retatrutide functions as a triple receptor agonist with differentiated activity across GLP-1, GIP, and glucagon receptors. Binding affinity occurs at nanomolar levels.
Reported EC50 values include:
GIP receptor: Approximately 0.064 nM
GLP-1 receptor: Approximately 0.775 nM
Glucagon receptor: Approximately 5.79 nM In research models, retatrutide activates several metabolic pathways.
- GLP-1 receptor activation reduces appetite through central signaling. It slows gastric emptying. It increases glucose-dependent insulin secretion. It also suppresses glucagon during hyperglycemia.
- GIP receptor activation enhances insulin release. It supports beta-cell function. It influences fat storage and metabolism.
- Glucagon receptor activation may increase energy expenditure and lipid metabolism, though its effects on glucose levels are carefully monitored in clinical trials.
This combined activity reduces food intake and improves insulin sensitivity. It also increases metabolic rate. Studies suggest a greater proportion of fat mass reduction compared to lean mass, though body composition outcomes may vary. This profile differs from single or dual agonists.
Peptide Profile of Retatrutide
Retatrutide is a synthetic peptide with 39 amino acids. It is engineered for stability and receptor potency. Specific sequence details remain proprietary. The peptide includes modifications that resist DPP-IV degradation. These changes also improve binding kinetics.
- Molecular formula: Not publicly disclosed
- Molecular weight: Estimated between 4,000 and 5,000 Da
- CAS or PubChem ID: Not assigned due to investigational status
- Form: Lyophilized acetate salt
This structure supports multi-receptor engagement. It is useful for studying incretin and glucagon signaling interactions.
Findings from Retatrutide Studies
Retatrutide shows strong results in metabolic research. Data come from preclinical studies and phase 2 trials.
1. Obesity Research About Retatrutide
A phase 2 randomized trial published in
NEJM included 338 adults. Participants had obesity or overweight with comorbidities. Once-weekly retatrutide produced dose-dependent weight loss. At
48 weeks, the 12 mg dose achieved about 24 percent weight reduction. Placebo groups showed minimal change. Most participants reached significant milestones.
Over 90 percent lost at least 10 percent body weight, and more than 80 percent lost at least 15 percent. Improvements were also noted in waist size, lipid levels, and blood pressure.
2. Type 2 Diabetes Research About Retatrutide
HbA1c reductions up to 2.02 percent were in phase 2 trials. Results exceeded those of the placebo and some comparator arms. Participants also experienced substantial weight loss.
3. Liver Fat and NAFLD Models
In participants with elevated liver fat, retatrutide reduced hepatic fat by over 80 percent. Most high-dose participants reached normal liver fat levels.
Additional Research Areas Where Retatrutide May Benefit
Phase 3 TRIUMPH trials study osteoarthritis, cardiovascular risk, kidney disease, and MASH. Some late-stage trial reports suggest weight reductions approaching 25–29% at higher doses over extended periods. Safety data show mostly mild gastrointestinal effects. These include nausea, diarrhea, and vomiting. Events are dose-related and often improve with titration. Serious hypoglycemia and major cardiac events remain rare in trials. Early data suggest greater efficacy than dual agonists. Retatrutide serves as a benchmark compound in triple-hormone research.
Disclaimer
Retatrutide is an investigational research compound. Currently, in 2026, it remains in phase 3 clinical trials. It is not approved for prescription or commercial use. Any non-trial products labeled as retatrutide may be counterfeit. Such products pose serious safety risks. Clinical and preclinical data do not guarantee future approval. No claims are made regarding safety or efficacy. Use is limited to qualified research settings. IRB or ethics approval is required for human studies. Regulatory restrictions may apply.
Referenced Citations
